Gastro-oesophageal Reflux Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Babies who are currently in a neonatal intensive care unit (NICU) and are between 37 and 47 weeks of postmenstrual age (this is the baby's age calculated from the mother's last menstrual period) at the time the study begins
- Babies who have been diagnosed with gastroesophageal reflux disease (GERD — a condition where stomach contents flow back up into the food pipe) confirmed by a specific monitoring test measuring acid and fluid movement in the food pipe
- Babies who are receiving all of their nutrition through feeding (no IV nutrition)
- Babies who are not currently receiving any treatments for GERD
Who may not be able to join:
- Babies who have a known serious chromosomal condition or complex birth syndrome
- Babies who have severe brain or nervous system problems that require brain surgery or medications that affect the nervous system
- Babies who require breathing support through a mask or device, or who need oxygen delivered at more than 4 litres per minute
- Babies who have malformations of the upper digestive tract that require surgery
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sudarshan R sudarshan.jadcherla@nationwidechildrens.org, Nationwide Children's Hospital
Phone: 6143556667
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Achievement of primary outcome: Improvement or maintenance of oral feeding and/or absence of GERD symptoms (based on feeding method at inception); Decrease in ARI on treatment; Decreased frequency of GER events on treatment; Improvement (Increase) in distal baseline impedance on treatment; Decrease in symptom associated probability on treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.